Recovery trial lead launches organisation to cut costs of clinical trials
BMJ 2022; 376 doi: https://doi.org/10.1136/bmj.o203 (Published 24 January 2022) Cite this as: BMJ 2022;376:o203- Elisabeth Mahase
- The BMJ
A new not-for-profit organisation, Protas, has been launched with the aim of designing and delivering more effective and accessible global clinical trials at a fraction of the current cost.
Protas, which has been initially supported by a grant from NHS England and a collaborative agreement with pharmaceutical company Sanofi, hopes to “radically readjust the economics of late stage randomised clinical trials,” thereby encouraging the development of better treatments for common conditions, the launch statement said.
It will work with industry partners, medical charities, patient groups, academic researchers, and clinical teams to do this.
The organisation is being led by Martin Landray, professor of medicine and epidemiology at the University of Oxford, who ran the Recovery trial …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £164 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.